AsitKPaulMDPhD

Genitourinary Oncology

Associate Professor of Medicine, Attending Physician, Hematology-Oncology, VCU Massey Cancer Center, VCU Medical Center, Virginia Commonwealth University

Join to view full profile

Dr. Paul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paul's full profile

Already have an account?

Office
1250 E Marshall St
Dept of IM Oncologyhematology
Richmond, VA 23298
Phone+1 804-828-7999

Fax+1 804-828-5941

Summary

Board Certified in Internal Medicine, Medical Oncology and Hematology. Practices in VCU Medical Center, VCU Massey Cancer Center, Richmond, VA

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Rochester General HospitalResidency, Internal Medicine, 2007 - 2010
Dhaka Medical CollegeClass of 1990

Certifications & Licensure

VA State Medical License 2013 - 2026
CA State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer Start of enrollment: 2017 Nov 03
Active, not recruiting
Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Start of enrollment: 2018 Sep 24
Recruiting
Phase 3
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Start of enrollment: 2019 Jun 07
Active, not recruiting
Phase 3
A Study of miRNA 371 in Patients With Germ Cell Tumors Start of enrollment: 2020 Jul 28
Recruiting
Join now to see all

Publications & Presentations

PubMed

48 citations
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Zhenjie Wu, Qi Chen, Le Qu, Mingmin Li, Linhui Wang
European Urology. 2022-04-01
40 citations
Sarcomatoid renal cell carcinoma: Biology and treatment advances
Nemer El Mouallem, Steven C. Smith, Asit K. Paul
Urologic Oncology. 2018-06-01
17 citations
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Joseph W Kim, Rana R McKay, Marc R Radke, Shilin Zhao, Mary-Ellen Taplin
Journal of Clinical Oncology. 2023-02-01

Press Mentions

Prostate Cancer: How Family History, Gene Variants Raise the Risks for Black MenDecember 6th, 2022
Prostate Cancer and the Higher Risk for Black MenDecember 6th, 2022
Stage Four Sarcomatoid Kidney Cancer Patient First to Show Complete Response to ImmunotherapyOctober 2nd, 2018

Research History

State University of New York, BuffaloMolecular Imaging, Antibody based targeted therapy in cancer2002 - 2007
Osaka University Graduate School of Medicine,JapanBiomedical Imaging1997 - 2002